JPRN-UMIN000024371已完成2 期
Phase II trial of S-1 plus Cetuximab combination chemotherapy for advanced recurrent/metastatic carcinoma of the oral cavity - S-1 plus Cetuximab combination chemotherapy for advanced recurrent/metastatic carcinoma of the oral cavity
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. History of hypersensitivity for the medicine of this study and the analogues. 2. receiving flucytocine. 3. possibly receiving flucytocine, HIV positive, or HBs antigen positive 4. Active infection requiring treatment. 5. Gastrointestinal disorder requiring treatment (paresis of intestine, ileus, etc). 6. Interstitial Pneumonia, pulmonary fibrosis 7. Uncontrolled diabetes mellitus. 8. Uncontrolled heart failure. 9. Severe liver failure. 10. Pregnant or lactating women or person in hope of the pregnancy of the partner. 11. Decision of ineligibility by a physician.
研究者
相似试验
已完成
2 期
Phase II trial of S-1 plus Cetuximab combination therapy in patients inappropriate for platinum-based therapy with recurrent/metastatic squamous cell carcinoma of the head and neckJPRN-UMIN000015123Hokkaido University21
招募中
不适用
Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancercolorectal cancerJPRN-UMIN000003703Toho University school of Medicine10
招募中
1 期
Phase1 trial of Cetuximab/S-1 combination therapy for Advanced/Recurrent Colorectal CancerJPRN-UMIN000004124Kinki university school of medicine Department of clinical oncology21
招募中
1 期
Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine.Colorectal cancer: KRAS wild typeJPRN-UMIN000003288Kyushu Medical Oncology Group40
尚未招募
1 期
Phase I/II trial of S-1+Nedaplatin+Cetuximab for recurrent/metastatic head and neck squamous cell carcinomahead and neck squamous cell carcinomaJPRN-UMIN000012074Kyorin University School of Medicine, Department of Otolaryngology30